With Lumasiran Pediatric Data, Alnylam Hopes For Approvals In All PH1 Patients

 
• By Joseph Haas

Alnylam shows that lumasiran offers similar safety and efficacy in primary hyperoxaluria type 1 patients who are six or younger as it does in older patients. US and EU regulatory decisions loom.

Kidney healthcare, doing medical research
Alnylam waits for US and EU regulatory decisions in rare kidney disorder

More from Clinical Trials

More from R&D